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PD-1/PD-L1 pathway plays a role in inhibiting immune response. Therapeutic antibodies
aimed at blocking the PD-1/PD-L1 interaction have entered clinical development and have
been approved for a variety of cancers. However, the clinical benefits are reduced to a group
of patients. The research in combined therapies, which allow for a greater response, is
strongly encouraging. We previously characterized a polyphenol-rich extract fromCaesalpinia
spinosa (P2Et) with antitumor activity in both melanoma and breast carcinoma, as well as
immunomodulatory activity. We hypothesize that the combined treatment with P2Et and anti-
PD-L1 can improve the antitumor response through an additive antitumor effect. We
investigated the antitumor and immunomodulatory activity of P2Et and anti-PD-L1
combined therapy in B16-F10 melanoma and 4T1 breast carcinoma. We analyzed tumor
growth, hematologic parameters, T cell counts, cytokine expression, and T cell cytotoxicity. In
the melanoma model, combined P2Et and anti-PD-L1 therapy has the following effects:
decrease in tumor size; increase in the number of activated CD4+ and CD8+ T cells; decrease
in the number of suppressor myeloid cells; increase in PD-L1 expression; decrease in the
frequency of CD8+ T cell expressing PD-1; improvement in the cytotoxic activity of T cells; and
increase in the IFNg secretion. In the breast cancer model, P2Et and PD-L1 alone or in
combination show antitumor effect with no clear additive effect. This study shows that
combined therapy of P2Et and anti-PD-L1 can improve antitumor response in a melanoma
model by activating the immune response and neutralizing immunosuppressive mechanisms.
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Cancer is a major public health problem and remains a main
cause of mortality and morbidity worldwide. Cancer patients
have traditionally been treated with chemotherapy and
radiotherapy despite their significant toxicity and lack of
effectiveness in all patients. In the last decade the role of the
immune system in the control of tumor growth and progression
has been well established, and several immunotherapies have
been designed. Cancer vaccines, antibody-mediated immune
modulation, adoptive T-cell transfer (1), and strategies to
induce immunogenic cell death (2) have been tested in
patients. However, to date immunotherapy has shown durable
clinical benefit in only a small subset of patients. Consequently,
the search for alternative treatments, therapies or combined
strategies against cancer is highly important (3).
Antibodies against immune-checkpoint molecules, as
programmed cell death protein-1 (PD-1), aim to neutralize
immunosuppression of tumor infiltrating lymphocytes (TILs)
have been approved for a variety of cancers (4–7). Unfortunately,
only a minority of patients benefit from this checkpoint blockade
across many types of cancer. These checkpoint inhibitors seem to
be more effective when there has been a prior immune system
activation associated with a sufficient number of TILs and a
higher expression of PD-1 ligand (PD-L1) on tumor cells (4, 5, 8,
9). Thus, to improve the number of patients who benefit from
PD-1 blockade, PD-1/PD-L1 antibodies are being used together
and/or in combination with other anticancer agents or
immunotherapies. The U.S. Food and Drug Administration
(FDA) has approved the uses of atezolizumab (a monoclonal
anti-PD-L1 antibody) in combination with albumin-linked
paclitaxel (nab-Paclitaxel) for the treatment of patients with
unresectable locally advanced or metastatic triple-negative
breast cancer tumors expressing PD-L1 (10).
In our previous studies, we got a gallotannin-rich extract from
Caesalpinia spinosa (P2Et) that has been previously reported to
have antitumor activity in murine melanoma and breast cancer
models (11–13). Caesalpinia spinose, commonly called Dividivi
or Tara has been traditionally used by Colombian indigenous
located on the Caribbean coast. It is a shrub with a pantropical
distribution in forests, savannas, and semi-deserts. Dividivi fruits
have 40 to 60% of hydrolyzable tannins with gallic acid as the
main constituent. Tannic acids present in Dividivi inhibit the
growth of tumors induced by chemical agents (14) and
the carcinogenesis induced by UV light in mice (15). Also,
gallic acid shows antioxidant, anti-allergenic, anti-mutagenic,
anti-carcinogenic, and anti-inflammatory properties (16) andAbbreviations: TILs, tumor infiltrating lymphocytes; PD-1, programmed cell
death protein-1; PD-L1, ligand of PD-1; FDA, Food and Drug Administration;
IFNg; Interferon gamma; ATP, adenosine triphosphate; NK, Natural killer; Treg,
Regulatory T cells; MDSCs, myeloid-derived suppressor cells; GAPDH,
Gliceraldehıd́o-3-fosfato deshidrogenasa; HIF-1a, Hypoxia-inducible factor-1a;
DCs, Dendritic cells; cDCs, Conventional Dendritic cells; TDLNs, tumor-draining
lymph nodes; MDSC-LCs, Myeloid-derived suppressor like cells; M-MDSC,
monocytic MDSC; PMN-MDSC, Polymorphonuclear MDSC; CoCl2,
Cobaltous chloride.
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melanoma (17, 18).
In our group, an extract derived from Caesalpinia spinosa
called P2Et was obtained, which was chemically normalized and
is now produced under good manufacturing practices (GMP) in
LABFARVE Labs. Multiple esters derived from gallic acid have
been reported, such as ethyl gallate, methyl gallate, ethyl 4,5-
digaloyl quinate, methyl 4,5-digaloyl quinate, ethyl 3,5-digaloyl
quinate, 4,5-digaloylquinic, ethyl 3,4,5-trigaloyl quinate, ethyl 5-
galloyl quinate, among others in this extract (19).
In our hands, P2Et extract induces immunogenic cell death,
displaying calreticulin on the cell surface, and ATP secretion in
both breast and melanoma models (19). Additionally, in B16-F10
melanoma model we demonstrated that P2Et’s antitumor activity
is partially abolished in immunodeficient mice, indicating that the
antitumor activity of the P2Et treatment is highly dependent on
the immune system (11). The treatment of C57BL/6 or BALB/c
healthy mice with P2Et increased the number of CD4+ and CD8+
activated T, NK, regulatory T, dendritic and MDSC cells in
lymphoid organs. However, in tumor-bearing animals, P2Et
decreased the number of intratumor myeloid-derived suppressor
cells (MDSCs) and increased the number of CD4+ and CD8+ T
cells (20), suggesting a role in the modulation of the immune
response, which is different in relation to the presence or not of
tumors. According to the above studies, we hypothesize that the
combined treatment with P2Et extract and anti-PD-L1 can
improve the antitumor response through an additive
antitumor effect.
In the present study, we investigated the antitumor and
immunomodulatory activity of P2Et and anti-PD-L1 combined
therapy in two different murine models, B16-F10 melanoma and
4T1 breast carcinoma. To this aim, we analyzed tumor growth,
hematologic parameters, T cell counts, cytokine expression, and
T cell cytotoxicity. Overall, we found that combined therapy with
P2Et and anti-PD-L1 improves the antitumor response in the
melanoma model by activating the immune response and
neutralizing immunosuppressive mechanisms. In contrast, and
surprisingly, no additive effect of the combination was observed
in the breast cancer model.MATERIALS AND METHODS
Plant Material
Caesalpinia spinosa pods were collected in Villa de Leyva, Boyacá,
Colombia and identified by Luis Carlos Jiménez from the
Colombian National Herbarium (voucher specimen number
COL 523714, Colombian Environmental Ministry agreement
number 1470 related to the use of genetic resources and derived
products). The P2Et extract was produced under GMP conditions
and chemically characterized as previously described (19, 21).
Mice
Young (6 to 12 weeks old) female C57BL/6 and BALB/c mice
were purchased from the Jackson Laboratories (Bar Harbor, ME,
USA) and housed at the animal facilities of the Pontificia
Universidad Javeriana (PUJ, Bogotá, Colombia) following theNovember 2020 | Volume 11 | Article 584959
Lasso et al. P2Et Enhances Anti-PD-L1 Therapy in Melanomaestablished protocols of the Ethics Committee of the Faculty of
Sciences, PUJ, and National and International Legislation for
Live Animal Experimentation (Colombia Republic, Resolution
08430, 1993; National Academy of Sciences, 2010). The present
study was approved by the ethics committee of the Faculty of
Sciences, PUJ, on August 9, 2018. Each specific protocol was also
approved by the animal experimentation committee of PUJ.
Mice were maintained in polyethylene cages with food and
water provided ad libitum, on a 12-h light/dark cycle at 20–22°
C and 40–60% humidity.
Tumor Cell Lines and Culture Conditions
B16-F10, 4T1, Mel-Rel, TS/A, MCF-7, MDA-MB-468, LAU 145,
and Me290 cell lines were cultured in RPMI-1640 (Eurobio,
Toulouse, France) supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, 100
mg/ml streptomycin, 0.01 M HEPES buffer, and 1 mM sodium
pyruvate (Eurobio) and incubated in a humidified environment
at 37°C and 5% CO2. Cells were grown until 75% confluency and
passaged using trypsin/1× EDTA (Eurobio), washed with PBS,
and resuspended in supplemented RPMI-1640.
Abs
The following Abs were used for cell surface staining: anti-CD3
Pacific Blue (clone 17A2), anti-CD8 PE Dazzle (clone 53.6.7),
anti-CD45 PE-Cy5 (clone 30-F11), anti-Ly-6G PE-Cy7 (clone
1A8), anti-Ly-6C APC-Cy7 (clone AL-21), anti-PD-L1 PE (clone
10F.9G2), anti-PD-1 APC (clone 29F-1A12), CD11b Alexa Fluor
700 (clone M1/70), B220 PE (clone RA-3-6B2) (Biolegend, San
Diego, CA, USA), anti-CD45 PE (clone 30-F11), anti-CD4
PerCP (clone RM4-5), Gr1 PE-Cy7 (clone RB6-8C5), CD11c
FITC (clone HL3), and anti-CD44 APC (clone IM7) (BD
Biosciences, San José, CA, USA). A LIVE/DEAD Fixable Aqua
Dead Cell Stain Kit (Life Technologies, Thermo Scientific,
Eugene, OR, USA) was used for dead cell exclusion.
In Vitro Induction of PD-L1
B16-F10 and 4T1 cells (1 × 105) were treated with half of P2Et IC50
(50% inhibition of cell growth), 100 mM of cobaltous chloride
(CoCl2, positive control) or ethanol (EtOH, negative control) for 6,
12, 24, or 48 h. Then, cells were harvested with TRIzol reagent
(Life Technologies Corporation, Invitrogen, NY, USA) and stored
at −80°C until further processing. In addition, cells were labeled
with anti-PD-L1 PE and analyzed by flow cytometry.
Reverse Transcription–Polymerase
Chain Reaction
Total RNA from B16-F10 or 4T1 treated cells in vitro, tumor cells
frommelanoma or 4T1 tumor-bearing mice or skin from healthy
C57BL6 or BALB/c mice, as control, was extracted using TRIzol
LS reagent (Life Technologies Corporation) in accordance with
the manufacturer’s instructions. Complementary DNA (cDNA)
was synthetized from total RNA with SuperScripts III Reverse
Transcriptase, following manufacturer’s instructions (Life
Technologies Corporation, Invitrogen, NY, USA). For real-
time PCR reaction, 600 ng of cDNA, DNA Master Plus SYBR
Green I (Roche Applied Science, IN, USA) and 250 nM forwardFrontiers in Immunology | www.frontiersin.org 3and reverse primers were added in a total volume of 20 µl. The
following primers were used: murine PD-L1 (forward:
CCATCCTGTTGTTCCTCATTG; reverse: CACTGCTTACG
TCTCCTCG), human PD-L1 (forward: GTACCGCTGCATG
ATCAGCTAT; reverse: GGCATTGACTTTCACAGTAAT
TCG) (22); murine glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (forward: TCAACAGCAACTCCCACTCTTCCA;
reverse: ACCCTGTTGCTGTAGCCGTATTCA); and human
b2-microglobuline (forward: TGGAGGCTATCCAGCGTACT;
reverse: CGGCAGGCATACTCATCTTT). Reactions were
performed in duplicates using QuantStudio 3 Real-Time PCR
systems (ThermoFisher Scientific, Waltham, MA, USA). The
relative expression level was normalized to murine GAPDH
expression or human b2-microglobuline and calculated using
the comparative CT method (2−DDCT).
In Vivo Tumor Development Experiments
and Treatment
For melanoma tumor induction, C57BL/6 mice were
subcutaneously (s.c.) inoculated in the right flank with 1 × 105
viable B16-F10 cells. For the breast cancer murine model, 1 × 104
viable 4T1 cells were s.c. injected into the right mammary fat pad of
BALB/c mice. To evaluate the effect of treatments on tumor growth,
3–5 days after tumor cell inoculation, 5–7 mice per group were
treated with 200 µg of anti-PD-L1 (clone: 10F.9G2; BioXcell, West
Lebanon, NH, USA), 75 mg/kg (B16-F10 model), or 18.7 mg/kg
(4T1 model) body weight of P2Et extract, anti-PD-L1 plus P2Et or
PBS (negative control) two times per week. To ensure low toxicity,
P2Et therapeutic dose was determined as a fourfold lower than the
median lethal dose (LD-50) estimation (11). In all experimental
settings, the size of the tumors was assessed three times per week
with Vernier calipers, and the volume was calculated according to
the formula V (mm3) = L (major axis) × W2 (minor axis)/2 (23).
Mice were euthanized by CO2 inhalation, and then spleen, tumor-
draining lymph nodes (TDLN), and tumor were removed and
processed. Looking for sufficient statistical power adjusted to the
standard deviation and to the proportion of losses in eachmodel, six
mice were included for each treatment group.
Hematology
Approximately 700 µl of blood was collected by cardiac puncture
immediately after euthanasia into tubes containing EDTA. A
part of the blood was used to evaluate hematological parameters
on the MICROS-60 hematology analyzer (Horiba ABX-
Diagnostics, Montpellier, France). The remaining blood was
used to separate plasma and evaluate cytokine levels.
Cytokine Assay
Cytokine evaluation was performed using a Cytometric Bead
Array (CBA) mouse Th1, Th2, Th17 cytokine kit (BD
Biosciences) according to the manufacturer’s instructions.
Experiments were performed twice, and each experiment was
performed in duplicate. Events were acquired using a FACSAria
II flow cytometer (BD Immunocytometry Systems), and the
results were subsequently analyzed using FCAP array software
version 3.0 (BD Biosciences). Data were log-transformed and
plotted as the mean ± SEM.November 2020 | Volume 11 | Article 584959
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Briefly, 1 × 106 cells were stained with LIVE/DEAD Fixable
Aqua for 20 min in dark conditions at room temperature.
After washing with PBS 2% FBS, the cells were stained for
30 min at 4°C in dark conditions with the surface antibodies at
final concentration of 1 µg/ml according to the designed
multicolor panels. Then, the cells were acquired by flow
cytometry using a FACSAria II flow cytometer (BD
Immunocytometry Systems, San José, CA, USA), and the
results were subsequently analyzed using FlowJo 9.3.2
software (Tree star, Ashland, OR).
Cytotoxicity Assay by Flow Cytometry,
CFSE/7-Amino Actinomycin D
To expand tumor-specific cytotoxic T cells, splenocytes (3 ×
106) from each group of B16-F10 or 4T1 tumor-bearing mice
were plated in 24-well plates. Cells were cultured in a total
volume of 3 ml of RPMI-1640 (Eurobio) supplemented with
10% FBS (Eurobio), 2 mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin, 0.01 M HEPES buffer, 1 mM sodium
pyruvate (Eurobio), IL-2 (10 UI/ml), IL-7 (1 ng/ml), and B16-
F10 or 4T1 cell lysate (20 µg/ml). The cells were then incubated
in a humidified environment at 37°C and 5% CO2 for four days.
Later, the cells were restimulated with the respective cell lysate
(20 µg/ml) and cultured for three additional days. Then, cells
were collected and resuspended in medium for the cytotoxicity
a s s a y . B16 -F10 o r 4T1 c e l l s we r e l a b e l e d w i t h
carboxyfluorescein succinimidyl ester (CFSE; Thermo Fisher
Scientific, MA, USA) at a final concentration of 1 µM for 20 min
at 37°C following the manufacturer’s recommendations. After
quenching, the labeling reaction was stopped by the addition of
complete culture medium, followed by a 5-min incubation at
37°C. After 2 washes, the CFSE-labeled target cells were
resuspended and used for the cytotoxicity assay. The cell
concentration was adjusted to 5 × 105 cells/ml, and 100 µl/
well, and plated into 96-well plates. Splenocytes were added at
10:1 and 20:1 effector-target (E:T) ratios. The plates were
incubated in a humidified atmosphere of 5% CO2 and 37°C.
After 12 h, the wells were harvested and labeled with 7-amino
actinomycin D (7-AAD) to stain dead cells. All cells in each
tube were acquired on a FACSAria II instrument (BD
Immunocytometry Systems) flow cytometer, and the results
were analyzed using FlowJo software (Tree Star). Analysis was
performed by gating on the target cells and measuring the 7-
AAD-positive cells (24). Cells positive for both 7-AAD and
CFSE were considered lysed. Additionally, we calculated the
percentage of cell loss in each well assuming that the number
of target cells read from the 0:1 effector–target ratio was 100%
of events (25). This percentage was added to the percentage of
dead cells, and the percentage of cytotoxic activity was
calculated using the following equation:
Cytotoxicity ( % )
=
100 x ½dead target cells ( % ) spontaneous death ( % )
½100 − spontaneous death ( % )Frontiers in Immunology | www.frontiersin.org 4Statistical Analysis
Statistical analysis of the significance between two groups was
calculated using the Mann–Whitney U test. Differences among
subject groups were evaluated using Kruskal–Wallis and Dunn’s
posttest for multiple comparisons. For all cases, the differences
were considered statistically significant when p < 0.05. GraphPad
Prism version 6.0 for Mac OS X statistics software (GraphPad
Software, San Diego, CA) was used for the statistical analyses.RESULTS
PD-L1 Expression Is Modulated by P2Et
Extract in B16-F10 and 4T1 Cells
In order to assess the impact of P2Et treatment on tumor PD-L1
expression, B16-F10 and 4T1 tumor cells were treated with sub-
lethal concentration of the extract (1/2 IC50), for variable exposure
times. We observed an upregulation of protein over time at
transcriptional or protein level, being the most significant at 48 h
of treatment (Supplementary Figure 1). In basal conditions, B16-
F10 cells exhibited higher levels of surface and total (surface and
intracellular) PD-L1 expression compared to 4T1 cells (Figure 1A).
The analysis of the gene expression of PD-L1 showed that P2Et
induces the transcription of PD-L1 mRNA in B16-F10 but not in
4T1 (Figure 1B). Analysis done after 48 h of stimulation, confirmed
that surface and intracellular PD-L1 expression on B16-F10 cells are
higher after P2Et treatment, compared with 4T1 (Figures 1C-F).
When comparing P2Et with the positive control CoCl2, a hypoxia
inducer that increases PD-L1 (26), it was observed that at least in
B16-F10, P2Et increases PD-L1 by a different signaling pathway
possibly independent of HIF-1a, (Figures 1B–D). To determine
whether the P2Et-mediated modulation of PD-L1 could be
generalized or is specific to these cell lines, we assessed PD-L1
expression on the murine melanoma cell line (Mel-Rel), the murine
breast cancer cell line (TS/A), the human melanoma (LAU 145 and
Me 290), and the human breast (MCF-7 andMDA-MB-468) cancer
cell lines. The increase in PD-L1-mRNA levels induced by P2Et was
observed in all human cell lines but not in TS/A and minimally in
Mel Rel murine cell lines (Supplementary Figure 1G). In contrast,
the surface level of PD-L1 was increased on TS/A, MCF-7 and Me
290 cell lines but, decreased in MDA-MB-468 and LAU 145, while
the intracellular PD-L1 level was increased in all human cell lines
but not in murine cell lines (Supplementary Figure 1H). These
results suggest that the effects of P2Et differ depending on the cell
line, regardless of tumor type and origin.
P2Et Treatment Enhances the Response
to aPD-L1 immunotherapy in B16-F10
Tumor-Bearing Mice
In addition to the properties of P2Et extract to induce
immunogenic cell death and to modulate the immune response
(11–13, 20), it also upregulates the PD-L1 expression in certain
cell lines, which could sensitize cancer cells to the anti-PD-L1
antibody. To check this hypothesis, we tested a combined
therapy of P2Et and anti-PD-L1 (aPD-L1) in B16-F10 tumor-November 2020 | Volume 11 | Article 584959
Lasso et al. P2Et Enhances Anti-PD-L1 Therapy in Melanomabearing mice (Figure 2A). 1 × 105 B16-F10 cells were injected s.c
to C57BL/6 mice, and 5 days after, mice were treated with P2Et,
aPD-L1, P2Et plus aPD-L1 or PBS. Mice treated with P2Et plus
aPD-L1 showed the smallest tumor size compared to the other
groups, even when compared to the P2Et only treated mice,
while therapy with only aPD-L1 did not impair tumor growth
compared to the PBS control group (Figure 2B). In addition,
mice treated with P2Et plus aPD-L1 showed a higher percentage
or survival (Supplementary Figure 3).Frontiers in Immunology | www.frontiersin.org 5In order to evaluate whether the modulation of PD-L1 on the
tumor cell could be related to a possible adjuvant activity of PD-
L1 in vivo, we evaluated the effect of combined therapy of P2Et
and aPD-L1 in 4T1 tumor-bearing mice (Figure 2A). Mice
treatment with P2Et delayed tumor growth as previously
observed (12, 20), but although aPD-L1 and P2Et plus aPD-
L1 treatments, as P2Et alone, had a positive effect on tumor
growth, no synergistic activity was observed on 4T1 tumor-
bearing mice (Figure 2C).A B
C D
E F
FIGURE 1 | P2Et treatment modulates the expression of PD-L1 on B16-F10 and 4T1 cells. (A) Geometric Mean Fluorescence Intensity (MFI) of surface or
intracellular PD-L1 expression in B16-F10 and 4T1 cells after 48 h. (B) PD-L1 relative expression to GAPDH gene in B16-F10 and 4T1 cultured cells during 48 h with
one-half of the P2Et IC50 extract, cobaltous chloride (CoCl2) or ethanol (EtOH) analyzed by qRT-PCR and quantitated as a fold change against the control by using
the 2−DDCT method. Representative histograms of surface and intracellular PD-L1 expression in (C) B16-F10 and (E) 4T1 cells treated during 48 h with one-half of
the P2Et IC50, CoCl2 or ethanol. Geometric MFI of surface and intracellular PD-L1 expression in (D) B16-F10 and (F) 4T1 cells treated. In all cases data are
represented as the mean ± SEM of at least three independent experiments. The p values were calculated using a Mann–Whitney U test or Kruskal–Wallis test with
Dunn’s post-test. *p < 0.05, **p < 0.01, ****p < 0.0001.November 2020 | Volume 11 | Article 584959
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with aPD-L1 Maintains Hematological
Parameters in Normal Ranges in B16-F10
Melanoma Model
P2Et extract has an important antioxidant activity (19) that
could protect host cells from oxidative stress during cancer
expansion and progression. Thus, we evaluated hematological
parameters in normal and treated tumor-bearing mice. In the
B16-F10 model, there was no change in leukocytes, platelets,
lymphocytes, monocytes, and granulocytes’ counts in mice
treated with P2Et alone or in combination with aPD-L1
compared with healthy mice (Figure 3A). Mice treated with
P2Et or P2Et plus aPD-L1 had a higher number of leukocytes,
lymphocytes, monocytes, and granulocytes compared to the
untreated mice. However, in the 4T1 model, the only
populations that remained in the normal range were platelets
in mice treated with P2Et plus aPD-L1, and monocytes and
granulocytes in mice treated with aPD-L1 (Figure 3B). In
conclusion, a significant recovery of hematological parameters
was evidenced in melanoma model when P2Et alone or in
combination with aPD-L1 was used.Frontiers in Immunology | www.frontiersin.org 6P2Et Treatment Increases PD-L1
Expression in Tumor Cells In Vivo
Given that the expression of PD-L1 in tumor cells may affect the
response to immune blockade therapy, we evaluated PD-L1
expression in tumor CD45 negative cells recuperated from
mice. In the melanoma model, P2Et extract alone or in
combination with aPD-L1 significantly increased surface PD-
L1, (Figures 4A, B) and PD-L1 mRNA expression in
tumors (Figure 4C). In contrast, it significantly decreased
the frequency of CD8+ T cells expressing PD-1 receptor
(Figure 4D). This suggests that P2Et can improve the effector
response of CD8+ T cells. P2Et treatment did not modulate the
PD-L1 expression in the breast 4T1 model in vivo (Figures 4E–
G) as previously shown (Figure 1) and neither did it modulate
the frequency of T cells expressing PD-1 (Figure 4H). In both
models, a significant decrease in PD-L1 surface expression after
aPD-L1 treatment compared with other groups (Figures 4A,
B, E, F) was found. However, there has been a diminution
due to a masking effect of therapeutic aPD-L1 antibody
(Supplementary Figure 2). This would explain the
discrepancy between protein level and mRNA expression inA
B C
FIGURE 2 | P2Et treatment enhances the response to anti-PD-L1 immunotherapy in B16-F10 tumor-bearing mice. (A) Experimental treatment scheme. Tumor was
established by injection of B16-F10 or 4T1 cells and 5 days after tumor cell injection, treatments were administrated two times per week for 17 and 33 days,
respectively. (A) Tumor volume in B16-F10 tumor-bearing mice treated with ⍺PD-L1, P2Et, P2Et plus aPD-L1 or PBS. (B) Tumor volume in 4T1 tumor-bearing mice
treated with each treatment. In all cases data are represented as the mean ± SEM (n = 6). The p values were calculated using a two-way ANOVA test. **p < 0.01,
****p < 0.0001.November 2020 | Volume 11 | Article 584959
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Recent studies have shown that adjacent cells around the tumor
(dendritic or macrophages), express higher levels of PD-L1 and
play an important role in the response to immunotherapy (8,Frontiers in Immunology | www.frontiersin.org 727, 28). Therefore, we assessed the PD-L1 expression also in
tumor infiltrating CD45+ cells in both models, but no
significant differences were found among the different
treatments (data not shown).A
B
FIGURE 3 | Hematological parameters. Hematological parameters of B16-F10 (A) or 4T1 tumor-bearing mice (B). Data are represented as violin plots showing the
frequency distribution of the data, median, and quartiles. The gray area shows the normal reference range for each mouse strain according to the breeding
company, and the dotted line corresponds to the median of the reference range. *p < 0.05, **p < 0.01.A B C D
E F G H
FIGURE 4 | PD-L1 and PD-1 expression in melanoma and breast tumor infiltrating immune cells. (A) Frequency of CD45 negative cells expressing PD-L1 in mice
treated with ⍺PD-L1, P2Et, P2Et plus ⍺PD-L1 or PBS (control). (B) MFI of PD-L1 expression in CD45 negative cells. (C) PD-L1 relative expression to GAPDH gene
in tumor cells from each mice group analyzed by qRT-PCR and quantitated as a fold change against the control (healthy mice) by using the 2−DDCT method.
(D) Frequency of intratumoral CD4+ and CD8+ T cells expressing PD-1. CD4+ and CD8+ T cells were selected from live CD3+ CD45+ cells. (E) Frequency of CD45
negative cells expressing PD-L1 in 4T1 tumor-bearing mice treated with ⍺PD-L1, P2Et, P2Et plus ⍺PD-L1 or PBS (control). (F) MFI of PD-L1 expression in CD45
negative cells from 4T1 tumor-bearing mice. (G) PD-L1 relative expression to GAPDH gene in tumor cells from each 4T1 tumor-bearing mice group analyzed by
qRT-PCR and quantitated as a fold change against the control (healthy mice) by using the 2−DDCT method. (H) Frequency of intratumoral CD4+ and CD8+ T cells
expressing PD-1 in 4T1 tumor-bearing mice. In all cases data are represented as the mean ± SEM. *p < 0.05, **p < 0.01.November 2020 | Volume 11 | Article 584959
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With aPD-L1 Modulates the Immune
Response
The fine analysis of the type of cells present in the tumor allowed
showing that the relationship between tumor cells and immune
cells varies depending on the type of treatment. Therefore, in
melanoma model the therapy with P2Et or P2Et plus aPD-L1
induces a significant increase in the number of tumor-infiltrating
CD45+ cells per mg of tissue, compared to PBS or aPD-L1
groups (Figure 5A). Within the CD45+ cells, the population of
CD4+ and CD8+ T cells was analyzed (Figure 5B) and an
increase of cell numbers was found in mice treated with P2Et
or with the combination (Figure 5C). In addition, P2Et or P2Et
plus aPD-L1 treatment, also induced a high frequency of
activated (CD44+) CD4+ and CD8+ T cells (Figure 5D). The
assessment of other immune cell populations in the tumor
(Figure 5E) showed that the three treatment strategies
decreased the number of MDSC, which due to lack of
functional evaluation are called myeloid-derived suppressor
like cells (MDSC-LCs) (Figure 5F) (29). However, the number
of tumor-infiltrating monocytic MDSC (M-MDSC) was lower
with P2Et plus aPD-L1 treatment compared to P2Et alone
(Figure 5F). Recently it was described that PD-L1 expression
on dendritic cells (DCs) and macrophages correlated with theFrontiers in Immunology | www.frontiersin.org 8efficacy of immunotherapy in ovarian cancer and melanoma
(30). We found that P2Et treatment increased the frequency
of conventional DCs (cDCs) in TDLN and also increased PD-L1
expression in these cells and in macrophages (Supplementary
Figures 4A, B), suggesting that the P2Et-based therapy
alone may trigger counter regulatory immune loops, thus
providing a rationale for combination with immune check
point blockade. However, no differences were found in the
spleen (Supplementary Figure 5).
Similar results were found in the 4T1 model. The treatment
with P2Et, aPD-L1 or P2Et plus aPD-L1 significantly increased
the number of CD45+ cel ls per mg of 4T1 tumor
(Supplementary Figure 6A), with an increase in CD4+ and
CD8+ T cells (Supplementary Figure 6B). Likewise, we found an
increase in the frequency of activated CD44+ CD4+ and CD44+
CD8+ T cells when treated with P2Et plus aPD-L1, and an
increase of CD44+ CD8+ T cells when treated with P2Et
(Supplementary Figure 6C). Moreover, we found a significant
decrease in the total number of MDSC-LC after all the
treatments compared with non-treated mice, mainly due to the
decrease in polymorphonuclear MDSC (PMN-MDSC) cells
(Supplementary Figure 6D). Furthermore, we showed that
P2Et plus aPD-L1 treatment increased the frequency of cDC,
and P2Et alone increased their PD-L1 expression. However, inA B
D E F
C
FIGURE 5 | P2Et treatment alone or in combination with aPD-L1 modulates the immune response in melanoma B16-F10 model. (A) Absolute numbers of CD45−
and CD45+ cells per mg of tumor in mice treated with ⍺PD-L1, P2Et, P2Et plus ⍺PD-L1 or PBS (control). (B) Representative dot plots of the CD4+ and CD8+ T cell
populations. (C) Absolute numbers of CD4+ and CD8+ T cells per mg of tumor in each group of treated mice. (D) Frequency of activated CD44+ CD4+ and CD8+ T
cells in tumor from each group of treated mice. (E) Representative dot plots of monocytic MDSC (M-MDSC: CD11b+ Ly6Chi Ly6G−) and polymorphonuclear MDSC
(PMN-MDSC: CD11b+ Ly6Clo Ly6G+). (F) Number of MDSC like cells (MDSC-LC), M-MDSC, and PMN-MDSC per mg of tumor from ⍺PD-L1, P2Et, P2Et plus ⍺PD-
L1 or PBS treated mice. In all cases data are represented as the mean ± SEM. *p < 0.05, **p < 0.01.November 2020 | Volume 11 | Article 584959
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groups (Supplementary Figures 4C, D).
P2Et in Combination With aPD-L1
Enhances the Effector Response of
Cytotoxic Cells in Melanoma and Breast
4T1 Model
To modulate the immune response in the B16-F10 melanoma
model based on the known capacity of P2Et, we evaluated the
production of cytokines in each group. Interestingly, a
significant increase in the plasma concentrations of IFNg
was found in the aPD-L1, P2Et and P2Et plus aPD-L1
groups compared to the control group, while a significant
decrease in the plasma concentrations of IL-10 was found
when P2Et was used (Figure 6A). In contrast, a significant
increase in the plasma concentrations of IL-10 and IL-17 wasFrontiers in Immunology | www.frontiersin.org 9found in aPD-L1 or P2Et plus aPD-L1 treated 4T1-BALB/c
mice as compared to B16-C57BL/c mice (Figure 6B) with a
downward trend in IL-6 (data not shown), confirming our
previous results (12). Taking into account the potential role of
IL-10 and IL-17 in tumor promotion (31–33), these results
may explain the differences in the treatment outcome in both
models . No differences were found in the plasma
concentrations of IL-4 and IL-2 (data not shown) between
groups. Finally, we also assessed the cytotoxic capacity of
spleen cells after expanding tumor-specific cytotoxic T cells,
as explained in the Materials and Methods section. We found
that P2Et plus aPD-L1 treatment induced a higher cytotoxic
potential of cytotoxic cells both in melanoma and in the breast
cancer model (Figures 6C, D), suggesting that combined
therapy improves CD8+ T cell effector functions, which
would entail a better response to immunotherapy.A
B
C D
FIGURE 6 | Effector response in melanoma and breast cancer. Cytokine levels in the serum of B16-F10 tumor-bearing mice (A) or 4T1 tumor-bearing mice (B)
treated with ⍺PD-L1, P2Et, P2Et plus ⍺PD-L1 or PBS (control). The data were log-transformed and plotted as the mean ± SEM. (C) Cytotoxicity percentage of
spleen cells from B16 tumor-bearing mice against B16-F10 melanoma cells at E:T ratios of 0:1, 10:1 and 20:1. (D) Cytotoxicity percentage of spleen cells from 4T1
tumor-bearing mice against 4T1 cells at E:T ratios of 0:1, 10:1 and 20:1. In all cases data are represented as the mean ± SEM. *p < 0.05, **p < 0.01.November 2020 | Volume 11 | Article 584959
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In the current study, we evaluated the combined treatment of
P2Et, a polyphenol-rich extract obtained from Caesalpinia
spinosa, and aPD-L1 antibody for melanoma and breast
cancer in mouse models. This in accordance with the fact that,
in breast cancer, there is no high response to immunotherapy
compared to that observed in other types of cancer such as
melanoma, lung, kidney cancer, among others (34). We confirm
the antitumor activity of P2Et both on melanoma B16-F10 and
breast cancer 4T1 tumor models (11, 13). We then demonstrate
that P2Et extract improves the response to treatment with aPD-
L1 antibody in the murine melanoma model, finding that the
combined therapy increases PD-L1 expression in tumor cells,
maintains most hematological parameters in the normal range,
modulates the immune response and enhances the effector
response of cytotoxic cells. By contrast although experiments
on the number of TILs and the effector response of cytotoxic cells
revealed favorable results in the breast cancer model, combined
therapy had no effects in tumor growth compared to individual
therapy with P2Et or aPD-L1. These results reflect the necessity
to evaluate individual heterogenicity of the response, and its
relationship with the tumor type and genetic background of
the individual.
We observed heterogenous responses of PD-L1 expression on
different tumor cells treated with P2Et extract. The mechanisms
governing the PD-L1 expression are not well understood (35).
PD-L1 is not only expressed in tumors, but also on the surface of
B lymphocytes, monocytes, natural killer cells, macrophages, and
vascular endothelial cells (36). However, the mechanisms
governing the expression on tumor cells and immune cells
seem to be different. Different polyphenols have been evaluated
in their ability to modulate the expression of PD-L1 or to
synergize with other therapies (37, 38). This seems to depend
on the microenvironment context, the dose of the compounds,
and the type of cells to which they are directed (39). A recent
study showed that two polyphenolic compounds, curcumin and
apigenin, decrease the PD-L1 expression on melanoma cells in
vitro and in vivo in a murine model, diminishing the tumor
growth and increasing immune cell infiltration (40).
Nonetheless, other studies have shown that an increase in PD-
L1 expression may enhance therapeutic effect of aPD-L1
antibodies. In fact, treatments with resveratrol and piceatannol
alone or in combination elicited an upregulation of PD-L1 in
some breast and colorectal cancer cell lines (37).
In tumors, PD-L1 expression can be regulated genetically and
epigenetically. Amplifications and deletions of the PD-L1 gene
have been identified on primary tumor cells, and both have been
related with worse prognosis of the disease (41). Complexity of
anti-PD-L1 treatment effectivity is evidenced by the observation
that in some melanoma patients with detection of PD-L1 by
immunohistochemistry, a positive clinical response to anti-PD-
L1 treatment has been observed, while a bad response have been
also observed in spite of a strong PD-L1 expression (42, 43). PD-
L1 levels may be upregulated by different intracellular signals as
Akt activation or PTEN dysfunction (44) or, by regulation ofFrontiers in Immunology | www.frontiersin.org 10micro-RNAs (45). Natural products act on these intracellular
signals modulating several tumorigenic signals (46), having also
effect on microRNAs. Therefore, the identification of
mechanisms involved in PD-L1 modulation by P2Et or other
natural products requires a holistic approach including integrate
omics science and systems biology.
As we mentioned before, mechanisms implied in PD-L1
expression on tumor and immune cells seems to be different.
The study of PD-L1 expression on non-small cell lung carcinoma
(NSCLC), shows that reduced methylation of the PD-L1
promoter on tumor but not immune cells, increases the PD-L1
expression in response to external stimuli (47). Immune
response by itself, regulates PD-L1 expression though
interferon signaling (48) and even signals inducing epithelial-
to-mesenchymal transition of tumor cells, improves tumor
responses to anti-PD-L1 antibodies (49).
In this study, we show that P2Et modulates the gene expression
of PD-L1, as well as their protein expression, and this differs
among the different cell lines studied. Although the factors
involved were not studied, it is important to highlight that while
the B16-F10 cell line increased gene expression and the protein
response to P2Et, the 4T1 line showed a significant increase only
in the presence of CoCl2. However, our results suggest that while
P2Et exerts an activating effect of PD-L1 expression on the B16-
F10 cells, it has little to no influence in 4T1 cells. These differences
appear to be related to the intrinsic differences of tumor cells, but
also to the in vivo tumor response in different mice strains.
Different mice strains may have different immune status and
thus may display different immune infiltrates in tumors which in
turn can influence the outcome of immunotherapy. Thus, Sellers
and al., have been shown immune variations specific to the strain
(50). The BALB/c mice are considered a Th2 prone strain, whereas
a Th1 response characterizes the C57BL/6 mice. Nevertheless, this
also depends on the type of stimulus (51). In this sense, the
production of IL-17 could explain some differences between the
strains. Although it is true that IL-17 has been correlated with
tumor progression in the 4T1 and B16 models (52, 53), we did not
observe important differences in the plasma levels of this cytokine
in the B16 model, but in the 4T1 model. Interestingly, treatment
with PD-L1 alone or accompanied by P2Et significantly increased
IL-17 in 4T1 mice, but not in B16. The mechanisms that regulate
the activation of LTh17 depend on complex orchestrations of
cytokines in the tumor microenvironment and their function can
be dual (54). For example, in breast cancer it has been clearly
observed that IL-23 induced by PGE2 (55) plays a very important
role in the recruitment and activation of LTh17 related to tumor
evolution. However, it is not clear what the role of PGE2 is in
melanoma, and if this complex cytokine interaction is going to
occur in the same way. In fact, it has recently been shown that IL-
23 plays a dual role in the antitumor immune response in
melanoma, depending on tumor immunogenicity (56).
Another important parameter that can influence the type of
response generated is the time and kinetics to which the
treatments are added. In this work, we chose to use both
treatments simultaneously; however, some experimental data
show that these factors can have an effect on the type ofNovember 2020 | Volume 11 | Article 584959
Lasso et al. P2Et Enhances Anti-PD-L1 Therapy in Melanomaresponse generated (57). Moreover, our results showed
heterogeneity in the modulation of PD-L1 expression in the
tumor microenvironment related with the tumor model.
Similarly, Grasselly et al. reported that the antitumor activity
of cytotoxic chemotherapy combined with immune checkpoint
inhibitors was model-dependent (57).
The protective activity of some polyphenols has been
previously reported (39, 58). However, there are few studies
where its protective potential in co-treatment with immune
checkpoints blockade has been evaluated (38). In previous
studies of our group, we have observed the potential of P2Et in
the induction of a specific antitumor immune response in both
B16-F10 (11, 20) and 4T1 (12, 13, 20) models. We have also
reported a preferential migration of CD45+ cells to the tumor
and peripheral lymphoid organs, allowing a better antigenic
presentation through the activation of DC and the decrease of
MDSCs and regulatory T cell suppressors (11, 20). These
findings suggest that P2Et can regulate PD-L1 expression both
directly acting on tumor cells, as previously exposed, but also by
the way of immune system modulation. It could not be ruled out
that other immune checkpoint inhibitors, similarly regulated,
might be modulated by this extract, favoring immune response
activation which might be evaluated. In this way, effectiveness of
the clinical response to the blockade of PD-L1 and PD-1 has been
associated with an increase in TILs (5–7, 12, 23), and in this work
we have shown that the use of P2Et favored the intra-tumoral
and peripheral activation of the immune response.
Moreover, in both models we observed that treatment with
P2Et alone or in combination with anti PD-L1 decreases the
frequency of intratumoral MDSC-LC (20). The MDSC are
currently presented as one of the main immunosuppressive
elements of the antitumor response (59). Indeed, the antitumor
activity of the polyphenols through the inhibition of the
suppressive function of the MDSC and other suppressor
mechanisms has been evidenced for the epigallocatechin gallate
and the curcuma, among others (60, 61). Other important effect
of P2Et in B16-F10 tumor-bearing mice was the increase of CD8+
T cells frequency but the decrease of the frequency of CD8+ T
cells expressing PD-1, suggesting that PD-1 low/neg cells are
expanding upon the treatment.
We demonstrate that mice receiving combined therapy had
strengthened T cell response. In tumor tissues, most of the
infiltrated T cells displayed an activated phenotype, which may
be correlated with a better effector response. In the spleen,
cytotoxic T cells showed greater cytotoxic activity and,
consequently, may be involved with better control of tumor
progression in both models. Comparable results have been
reported using a curcumin analogue in combination with anti-
PD-L1 in murine bladder cancer (38), perhaps because curcumin
has been shown to stimulate the immune response (62), as well as
P2Et extract (11, 12, 20).
In summary, these findings suggest that P2Et extract
sensitizes B16-F10 cells by increasing PD-L1 expression for an
enhanced response to PD-L1 blockade, effect not found in
murine breast cancer model, achieving that combinationFrontiers in Immunology | www.frontiersin.org 11treatment improve antitumor response in the melanoma model
by enhancing CD8+ T cells activity and suppressing MDSCs.DATA AVAILABILITY STATEMENT
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